Tertiary Butylhydroquinone vs Acesulfame Potassium: which is worse?

What is Tertiary Butylhydroquinone?

Tertiary butylhydroquinone (TBHQ) is a synthetic phenolic antioxidant preservative derived from butane. It is one of the most potent antioxidants for polyunsaturated fats and oils and is commonly used in fast-food frying oils. Its chemical formula is C10H14O2.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Tertiary Butylhydroquinone: At high doses in animal studies, TBHQ has been shown to cause precancerous stomach lesions (squamous cell hyperplasia) in female rats. A study in Food and Chemical Toxicology documented these dose-dependent precancerous changes. The FDA limits TBHQ to 0.02% of fat content, reflecting dose-dependent safety thresholds. Immune function concerns emerged from research published around 2019-2020. A study (Farouk Musa and colleagues) found that TBHQ impaired the adaptive immune response to influenza in mouse models, including reduced effectiveness of influenza vaccination. EWG highlighted this research in its analysis. These findings have not been confirmed in human clinical trials but raised new dimensions of concern beyond cancer. Neurotoxicity: animal studies have documented TBHQ can cause precursors to certain types of cell injury in neural tissue at high doses, though effects at typical dietary exposure are not established. Allergic reactions including urticaria and contact dermatitis from TBHQ-containing cosmetics and personal care products are documented in dermatology literature. Japan banned TBHQ for food use. The EU restricts it in baby food (completely banned) and in adult food categories with maximum permitted levels. Australia and the UK restrict it.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.